China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The collaboration targets the central laboratory program, aiming to enhance clinical studies and drug development plans centered around TruSight Oncology 500 (TSO 500), a research-only pan-cancer detection assay.
TSO 500 Profile
TSO 500 is designed to identify known and unknown tumor biomarkers in 523 genes. The assay uses DNA and RNA from tumor samples to detect key mutations critical to cancer development and progression, including small DNA mutations, fusions, and splicing mutations. Additionally, TSO 500 evaluates key immune tumor biomarkers such as tumor mutation burden (TMB) and microsatellite instability (MSI), and assesses homologous recombination repair defects (HRD). This comprehensive approach aims to provide a deeper understanding of cancer biology and support the development of targeted therapies.
Partnership Objectives
The partnership between Adicon and Illumina underscores a commitment to advancing cancer research and improving patient outcomes. By leveraging TSO 500, the collaboration aims to enhance the detection and analysis of cancer biomarkers, supporting the development of more effective treatments and personalized medicine approaches.-Fineline Info & Tech
